Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Pennsylvania
About this trial
This is a pilot, open-label study to assess the safety and feasibility of using investigational drug(s) as rescue therapies for CAR T cell related CRS and HLH-like syndrome (CRHLS).
Eligibility criteria
Qualifiers
Signed, written informed consent
Male or female patients age ≥ 18 years
Have been co-enrolled in a University of Pennsylvania-Sponsored, CCI-Initiated CAR T cell clinical trial.
Subjects of reproductive potential must agree to use acceptable birth control methods, as described in protocol
Disqualifiers
Pregnant or nursing (lactating) women.
Known hypersensitivity to the active substance or one of the excipients of the investigational product(s).
Trial design
Treatments tested in this trial
- Tadekinig alfa (IL-18BP)
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov